Novartis Tells FDA Skinny Labels Won't Work With $3.5B Drug
Novartis Pharmaceuticals has urged the U.S. Food and Drug Administration to reject generic versions of its blockbuster heart failure drug Entresto until its exclusivity expires in 2024, even if the generic-drug...To view the full article, register now.
Already a subscriber? Click here to view full article